阿比特龙治疗mCRPC的临床应用进展
Progress in Clinical Application of Abiraterone in the Treatment of mCRPC
DOI: 10.12677/ACM.2021.1111815, PDF,   
作者: 张院冬：青海大学研究生院，青海 西宁；任海林*：青海大学附属医院，青海 西宁
关键词: 转移性去势抵抗性前列腺癌；醋酸阿比特龙；治疗序列；Metastatic Castration-Resistant Prostate Cancer； Abiraterone Acetate； Sequence Therapy
摘要: 前列腺癌(prostate cancer, PC)是男性发病率较高的一种疾病，在高收入国家和低收入国家之间，患病率差异很大。转移性前列腺癌(metastatic prostate cancer, mPC)是一种危及患者生命的疾病，也是一个重要的公共卫生问题，近几十年来，雄激素剥夺疗法(androgen deprivation therapy, ADT)一直是主要的治疗手段，可暂时控制疾病。随着新型内分泌治疗药物(以阿比特龙为代表)问世，转移性前列腺癌(mPC)治疗进入了内分泌治疗新时代。醋酸阿比特龙(abiraterone acetate, AA)是CYP17酶的选择性抑制剂，国内及国外的相关临床试验研究了其在转移性去势抵抗前列腺癌(metastatic castration-resistant prostate cancer, mCRPC)治疗过程中的有效性及安全性，醋酸阿比特龙联合泼尼松能够显著提高患者总生存期以及肿瘤无进展生存期，提高患者生活质量。本文对阿比特龙以及mCRPC进行介绍，凸显阿比特龙在治疗方面的重要性。就阿比特龙以及mCRPC近年的研究进展作一综述。目的是提供关于醋酸阿比特龙(AA)在mCRPC阶段的有效性和安全性证据数据，包括其作用机制和副作用。
Abstract: Prostate cancer (PC) is a disease with a high incidence in men, and prevalence varies widely between high and low-income countries. Metastatic prostate cancer (mPC) is a life-threatening disease and an important public health problem, and androgen deprivation therapy (ADT) has been the mainstay of treatment in recent decades to temporarily control the disease. With the advent of new endocrine therapy drugs (represented by abiraterone acetate), the treatment of metastatic prostate cancer has entered a new era of therapy. Abiraterone acetate (AA) is a selective inhibitor of CYP17, and its efficacy and safety in the treatment of mCRPC have been studied in domestic and foreign clinical trials. Abiraterone acetate combined with prednisone can significantly improve the overall survival and progression-free survival of patients, and improve the quality of life of patients. This article introduces abiraterone acetate and mCRPC, highlighting the importance of abiraterone acetate in treatment and summarizes the research progress of abiraterone acetate and mCRPC in recent years. The objective is to provide data on the efficacy and safety of abiraterone acetate in the mCRPC phase, including its mechanism of action and side effects.
文章引用：张院冬, 任海林. 阿比特龙治疗mCRPC的临床应用进展[J]. 临床医学进展, 2021, 11(11): 5507-5513. https://doi.org/10.12677/ACM.2021.1111815

参考文献

[1] Rawla, P. (2019) Epidemiology of Prostate Cancer. World Journal of Oncology, 10, 63-89. [Google Scholar] [CrossRef] [PubMed]
[2] Stangelberger, A., Waldert, M. and Djavan, B. (2008) Prostate Cancer in Elderly Men. Reviews in Urology, 10, 111-119.
[3] 叶定伟. 前列腺癌的流行病学和中国的发病趋势[J]. 中华外科杂志, 2006, 44(6): 362-364.
[4] Pagliarulo, V., Bracarda, S., Eisenberger, M.A., et al. (2012) Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. European Urology, 61, 11-25. [Google Scholar] [CrossRef] [PubMed]
[5] Tannock, I.F., De Wit, R., Berry, W.R., et al. (2004) Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. The New England Journal of Medicine, 351, 1502-1512. [Google Scholar] [CrossRef] 
[6] Dayyani, F., Gallick, G.E., Logothetis, C.J., et al. (2011) Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. Journal of the National Cancer Institute, 103, 1665-1675. [Google Scholar] [CrossRef] [PubMed]
[7] Robinson, D., Van Allen, E.M., Wu, Y.M., et al. (2015) Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 161, 1215-1228. [Google Scholar] [CrossRef] [PubMed]
[8] Buttigliero, C., Tucci, M., Bertaglia, V., et al. (2015) Understanding and Overcoming the Mechanisms of Primary and Acquired Resistance to Abiraterone and Enzalutamide in Castration Resistant Prostate Cancer. Cancer Treatment Reviews, 41, 884-892. [Google Scholar] [CrossRef] [PubMed]
[9] De Bono, J.S., Logothetis, C.J., Molina, A., et al. (2011) Abiraterone and Increased Survival in Metastatic Prostate Cancer. The New England Journal of Medicine, 364, 1995-2005. [Google Scholar] [CrossRef] 
[10] Ryan, C.J., Smith, M.R., De Bono, J.S., et al. (2013) Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. The New England Journal of Medicine, 368, 138-148. [Google Scholar] [CrossRef] 
[11] Sternberg, C.N., Molina, A., North, S., et al. (2013) Effect of Abiraterone Acetate on Fatigue in Patients with Metastatic Castration-Resistant Prostate Cancer after Docetaxel Chemotherapy. Annals of Oncology, 24, 1017-1025. [Google Scholar] [CrossRef] [PubMed]
[12] Harland, S., Staffurth, J., Molina, A., et al. (2013) Effect of Abiraterone Acetate Treatment on the Quality of Life of Patients with Metastatic Castration-Resistant Prostate Cancer after Failure of Docetaxel Chemotherapy. European Journal of Cancer, 49, 3648-3657. [Google Scholar] [CrossRef] [PubMed]
[13] Logothetis, C.J., Basch, E., Molina, A., et al. (2012) Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial. The Lancet Oncology, 13, 1210-1217. [Google Scholar] [CrossRef] 
[14] Pereira-Salgado, A., Kwan, E.M., Tran, B., et al. (2021) Systematic Review of Efficacy and Health Economic Implications of Real-World Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? European Urology Focus, 7, 752-763. [Google Scholar] [CrossRef] [PubMed]
[15] Tran, C., Ouk, S., Clegg, N.J., et al. (2009) Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science, 324, 787-790. [Google Scholar] [CrossRef] [PubMed]
[16] Scher, H.I., Fizazi, K., Saad, F., et al. (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. The New England Journal of Medicine, 367, 1187-1197. [Google Scholar] [CrossRef] 
[17] Khalaf, D.J., Annala, M., Taavitsainen, S., et al. (2019) Optimal Sequencing of Enzalutamide and Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: A Multicentre, Randomised, Open-Label, Phase 2, Crossover Trial. The Lancet Oncology, 20, 1730-1739. [Google Scholar] [CrossRef] 
[18] Maughan, B.L., Luber, B., Nadal, R., et al. (2017) Comparing Sequencing of Abiraterone and Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. Prostate, 77, 33-40. [Google Scholar] [CrossRef] [PubMed]
[19] Antonarakis, E.S., Lu, C., Luber, B., et al. (2015) Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 1, 582-591. [Google Scholar] [CrossRef] [PubMed]
[20] Sciarra, A., Gentilucci, A., Silvestri, I., et al. (2019) Androgen Receptor Variant 7 (AR-V7) in Sequencing Therapeutic Agents for Castratrion Resistant Prostate Cancer: A Critical Review. Medicine (Baltimore), 98, e15608. [Google Scholar] [CrossRef] 
[21] Esch, L., Schulz, W.A. and Albers, P. (2014) Sequential Treatment with Taxanes and Novel Anti-Androgenic Compounds in Castration-Resistant Prostate Cancer. Oncology Research and Treatment, 37, 492-498. [Google Scholar] [CrossRef] [PubMed]
[22] Lorente, D., Mateo, J., Perez-Lopez, R., et al. (2015) Sequencing of Agents in Castration-Resistant Prostate Cancer. The Lancet Oncology, 16, e279-e292. [Google Scholar] [CrossRef] 
[23] Ang, J.E., Olmos, D. and De Bono, J.S. (2009) CYP17 Blockade by Abiraterone: Further Evidence for Frequent Continued Hormone-Dependence in Castration-Resistant Prostate Cancer. British Journal of Cancer, 100, 671-675. [Google Scholar] [CrossRef] [PubMed]
[24] Devore, N.M. and Scott, E.E. (2012) Structures of Cytochrome P450 17A1 with Prostate Cancer Drugs Abiraterone and TOK-001. Nature, 482, 116-119. [Google Scholar] [CrossRef] [PubMed]
[25] Bouhajib, M. and Tayab, Z. (2019) Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. Clinical Drug Investigation, 39, 309-317. [Google Scholar] [CrossRef] [PubMed]
[26] Chi, K.N., Spratlin, J., Kollmannsberger, C., et al. (2015) Food Effects on Abiraterone Pharmacokinetics in Healthy Subjects and Patients with Metastatic Castration-Resistant Prostate Cancer. The Journal of Clinical Pharmacology, 55, 1406-1414. [Google Scholar] [CrossRef] [PubMed]
[27] Szmulewitz, R.Z., Peer, C.J., Ibraheem, A., et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone with Food versus Standard Dose Abiraterone in Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 36, 1389-1395. [Google Scholar] [CrossRef] 
[28] Del Re, M., Fogli, S., Derosa, L., et al. (2017) The Role of Drug-Drug Interactions in Prostate Cancer Treatment: Focus on Abiraterone Acetate/Prednisone and Enzalutamide. Cancer Treatment Reviews, 55, 71-82. [Google Scholar] [CrossRef] [PubMed]
[29] Monbaliu, J., Gonzalez, M., Bernard, A., et al. (2016) In Vitro and in Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. Drug Metabolism & Disposition, 44, 1682-1691. [Google Scholar] [CrossRef] [PubMed]
[30] Auchus, R.J., Yu, M.K., Nguyen, S., et al. (2014) Use of Prednisone with Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer. Oncologist, 19, 1231-1240. [Google Scholar] [CrossRef] [PubMed]
[31] Fenioux, C., Louvet, C., Charton, E., et al. (2019) Switch from Abiraterone plus Prednisone to Abiraterone plus Dexamethasone at Asymptomatic PSA Progression in Patients with Metastatic Castration-Resistant Prostate Cancer. BJU International, 123, 300-306. [Google Scholar] [CrossRef] [PubMed]
[32] 杨振宇, 叶阳天, 李志勇, 等. 泼尼松转换为地塞米松治疗mCRPC的疗效分析[J]. 中华泌尿外科杂志, 2020, 41(8): 597-602.
[33] Colomba, E., Marret, G., Baciarello, G., et al. (2020) Liver Tests Increase on Abiraterone Acetate in Men with Metastatic Prostate Cancer: Natural History, Management and Outcome. European Journal of Cancer, 129, 117-122. [Google Scholar] [CrossRef] [PubMed]

为你推荐